LPCN

Lipocine Inc

1.46

Nov 03 • 4:00 PM ET +0.01 (0.69%)

1.43

Aftermarket • 5:33 PM ET -0.03 (-2.05%)

Healthcare Biotechnology USA Nano NASD

Peers: PTN DARE ORMP RANI ENTX VERU SKYE AEON MTNB CING

| Held by: VTI VXF DFSU DCOR DFMC DFAC DXUV

Scroll to Statements

Index	-
Market Cap	12.04M
Enterprise Value	-11.23M
Income	-11.85M
Sales	1.57M
Book/sh	2.64
Cash/sh	2.82
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	14
IPO	Jun 15, 2012

P/E	-
Forward P/E	-
PEG	-
P/S	7.67
P/B	0.55
P/C	0.52
P/FCF	-
EV/EBITDA	-
EV/Sales	-7.15
Quick Ratio	11.48
Current Ratio	11.48
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-1.86
EPS next Y	-1.34
EPS next Q	-0.35
EPS this Y	8.58%
EPS next Y	13.27%
EPS next 5Y	17.47%
EPS past 3/5Y	5.11% 22.70%
Sales past 3/5Y	58.12% -
EPS Y/Y TTM	-121.27%
Sales Y/Y TTM	-62.70%
EPS Q/Q	22.54%
Sales Q/Q	-69.48%
Earnings	Aug 04 BMO
EPS/Sales Surpr.	20.00% -10.75%

Insider Own	4.98%
Insider Trans	10.08%
Inst Own	36.17%
Inst Trans	-7.00%
ROA	-55.89%
ROE	-60.94%
ROIC	-54.45%
Gross Margin	96.27%
Oper. Margin	-800.82%
Profit Margin	-755.13%
SMA20	-8.75%
SMA50	-25.54%
SMA200	-61.75%
Trades

Shs Outstand	8.24M
Shs Float	7.83M
Short Float	4.49%
Short Ratio	0.20
Short Interest	0.35M
52W High	12.37 -88.20%
52W Low	1.36 7.35%
Volatility	5.77% 9.37%
ATR (14)	0.13
RSI (14)	32.82
Beta	0.50
Rel Volume	0.11
Avg Volume	1.78M
Volume	188,403

Perf Week	0.00%
Perf Month	-29.47%
Perf Quarter	-32.72%
Perf Half Y	-37.34%
Perf YTD	-81.82%
Perf Year	-44.91%
Perf 3Y	-43.41%
Perf 5Y	-92.26%
Perf 10Y	-97.19%
Recom	2.00
Target Price	5.00
Prev Close	1.45
Price	1.46
Change %	0.69%

Consensus

Buy

Avg. Price Target

$5.00

Implied Upside

+242.5%

Analysts5incl. previous ratings

Rating Distribution3 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Apr 06, 2026	Downgrade	HH.C. Wainwright	Buy → Neutral
Jun 24, 2021	Initiated	CCantor Fitzgerald	Overweight	$3	+105.5%
Dec 10, 2020	Upgrade	LLadenburg Thalmann	Neutral → Buy	$3	+105.5%
Jan 12, 2018	Reiterated	HH.C. Wainwright	Buy	$10 → $3	+105.5%
Jan 11, 2018	Downgrade	CCanaccord Genuity	Buy → Hold	$11 → $2	+37.0%
Dec 08, 2017	Resumed	HH.C. Wainwright	Buy	$10	+584.9%
Oct 07, 2016	Initiated	HH.C. Wainwright	Buy	$25	+1,612.3%
Jul 22, 2015	Initiated	RROTH Capital	Buy	$36	+2,365.8%
Jun 23, 2015	Initiated	CCanaccord Genuity	Buy	$15	+927.4%

Oct-07-26 10:01AM	Lipocine Health Canada Approval Clears TLANDO for Canadian Testosterone Replacement Market (InvestorsHub)
09:24AM	Lipocine stock surges 30% on Health Canada drug approval (Investing.com)
08:44AM	LPCN Stock Is Surging: Heres Why Lipocine Is On Traders Radar Today (Stocktwits)
08:00AM	Lipocine Announces Health Canada Approval of TLANDO for Testosterone Replacement Therapy (PR Newswire)
Sep-14-26 08:00AM	Lipocine Announces Initiation of BLOOM Phase 3 Study of LPCN 1154 for Postpartum Depression (PR Newswire)
08:00AM	Loading…
Sep-10-26 08:00AM	Lipocine to Present at the H.C. Wainwright 28th Annual Global Investment Conference (PR Newswire)
Aug-04-26 08:00AM	Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026 (PR Newswire)
06:21AM	Lipocine: Q2 Earnings Snapshot (Associated Press)
Aug-03-26 08:00AM	Lipocine Appoints Michael J. Grissinger to Board of Directors (PR Newswire)
Jun-04-26 08:00AM	Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154 (PR Newswire)
May-19-26 08:00AM	Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting (PR Newswire)
May-18-26 08:00AM	Lipocine to Present at A.G.P.'s Annual Virtual Healthcare Company Showcase (PR Newswire)
May-07-26 04:05PM	Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 (PR Newswire)
02:11PM	Lipocine: Q1 Earnings Snapshot (Associated Press)
Apr-02-26 08:00AM	Lipocine Reports Topline Safety and Efficacy Results for LPCN 1154 in Patients with Postpartum Depression (PR Newswire) -77.84%
08:00AM	Loading…
Mar-10-26 08:00AM	Lipocine Announces Financial Results for the Full Year Ended December 31, 2025 (PR Newswire)
06:25AM	Lipocine: Q4 Earnings Snapshot (Associated Press Finance)
Feb-27-26 07:44AM	Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock? (Zacks)
Feb-26-26 06:00PM	Relay Therapeutics, Inc. (RLAY) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +5.49%
Feb-18-26 08:00AM	Lipocine Announces Last Patient Last Visit in Pivotal Phase 3 Trial of LPCN 1154 for Postpartum Depression (PPD) (PR Newswire)
Feb-11-26 03:16PM	Buy Rating Maintained on Lipocine Inc. (LPCN) as Target Climbs to $15 (Insider Monkey)
Jan-20-26 08:00AM	Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) (PR Newswire) -10.87%
Jan-12-26 08:00AM	Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) (PR Newswire) +12.73%
Dec-16-25 08:00AM	Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone (PR Newswire)
Nov-18-25 08:00AM	Lipocine Highlights Promising Interim Safety Profile in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD) (PR Newswire) +12.67%
Nov-06-25 09:10AM	Lipocine (LPCN) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:12AM	Lipocine: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2025 (PR Newswire)
Nov-04-25 08:00AM	Lipocine Presents LPCN 2401 Clinical Data at ObesityWeek (PR Newswire)
Sep-30-25 08:00AM	Lipocine Provides Progress Update on LPCN 1154 Phase 3 Clinical Trial in Postpartum Depression (PPD) (PR Newswire)
04:30PM	Loading…
Sep-05-25 04:30PM	Lipocine to Present at H.C. Wainwright 27th Annual Global Investment Conference (PR Newswire)
Aug-26-25 08:00AM	Lipocine Announces LPCN 2101 Abstracts Accepted for Presentation at AES 2025 (PR Newswire)
Aug-05-25 08:00AM	Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025 (PR Newswire)
06:21AM	Lipocine: Q2 Earnings Snapshot (Associated Press Finance)
Jun-27-25 07:28AM	Lipocine begins dosing in Phase III postpartum depression trial of LPCN 1154 (Clinical Trials Arena)
Jun-26-25 08:00AM	Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression (PR Newswire)
Jun-23-25 08:00AM	Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO) as a Treatment for Postpartum Depression on July 9, 2025 (PR Newswire)
Jun-09-25 08:00AM	Lipocine Announces Filing of New Drug Submission for TLANDO in Canada (PR Newswire) +6.31%
May-22-25 08:00AM	Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology (PR Newswire)
May-14-25 08:00AM	Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase (PR Newswire) +10.10%
May-08-25 08:12AM	Lipocine: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025 (PR Newswire)
May-06-25 08:00AM	Lipocine Announces License and Supply Agreement for TLANDO in Brazil (PR Newswire)
Mar-27-25 12:03PM	Lipocines Phase III trial of LPCN 1154 to begin for postpartum depression (Clinical Trials Arena)
Mar-26-25 08:00AM	Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 (PR Newswire)
Mar-13-25 08:00AM	Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 (PR Newswire)
Mar-12-25 08:00AM	Lipocine Announces FDA Labeling Changes for Testosterone Products (PR Newswire)
Feb-06-25 08:00AM	Lipocine Receives Updated Regulatory Guidance on LPCN 1154 (PR Newswire) -14.67%
Dec-17-24 08:00AM	FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis (PR Newswire)
Nov-18-24 08:00AM	Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session (PR Newswire)
Nov-07-24 08:00AM	Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024 (PR Newswire) -7.76%
06:25AM	Lipocine: Q3 Earnings Snapshot (Associated Press Finance)
Oct-31-24 08:00AM	Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO in South Korea (PR Newswire)
Oct-10-24 08:00AM	Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results (PR Newswire)
Oct-09-24 08:06AM	Lipocine signs supply and distribution agreement with Pharmalink for Tlando (TipRanks)
Oct-08-24 08:00AM	Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO in the Gulf Cooperation Council (GCC) Countries (PR Newswire) +6.21%
Oct-02-24 08:00AM	Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024 (PR Newswire)
Sep-30-24 08:00AM	Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference (PR Newswire)
Sep-05-24 08:00AM	Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek (PR Newswire)
Aug-27-24 08:00AM	Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference (PR Newswire)
Aug-08-24 08:00AM	Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024 (PR Newswire) -12.90%
06:32AM	Lipocine: Q2 Earnings Snapshot (Associated Press Finance)
Jun-25-24 08:00AM	Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study (PR Newswire) -12.37%
Jun-10-24 08:00AM	Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024 (PR Newswire) +6.12%
Jun-06-24 08:50AM	Lipocine (LPCN) Is a Great Choice for 'Trend' Investors, Here's Why (Zacks)
May-28-24 06:10AM	7 Penny Biotech Stocks to Triple Your Investment (InvestorPlace)
May-21-24 08:50AM	Here's Why Momentum in Lipocine (LPCN) Should Keep going (Zacks)
May-09-24 01:53PM	LPCN Stock Earnings: Lipocine Beats EPS for Q1 2024 (InvestorPlace) +8.04%
08:00AM	Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024 (PR Newswire)
06:24AM	Lipocine: Q1 Earnings Snapshot (Associated Press Finance)
May-08-24 08:00AM	Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024 (PR Newswire)
May-01-24 08:00AM	Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154 (PR Newswire)
Apr-11-24 07:00AM	Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity (PR Newswire)
Mar-28-24 08:00AM	Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis (PR Newswire)
Mar-25-24 08:00AM	Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154 (PR Newswire) +8.91%
Mar-07-24 02:52PM	LPCN Stock Earnings: Lipocine Beats EPS for Q4 2023 (InvestorPlace)
08:00AM	Lipocine Announces Financial Results for the Full Year Ended December 31, 2023 (PR Newswire)
Mar-06-24 08:00AM	Lipocine to Present at 36th Annual Roth Conference (PR Newswire)
Feb-06-24 08:00AM	Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154 (PR Newswire)
Feb-02-24 08:00AM	Lipocine Announces Continued Commercialization of TLANDO through Verity Pharmaceuticals (PR Newswire)
Jan-18-24 08:00AM	Lipocine and Verity Pharma Enter into License Agreement for TLANDO Franchise in the U.S. and Canada (PR Newswire)
Dec-19-23 08:00AM	Lipocine to Present at Biotech Showcase 2024 (PR Newswire) +11.41%
Nov-13-23 02:45PM	Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting 2023 (PR Newswire) +11.20%
Nov-08-23 08:17AM	Lipocine: Q3 Earnings Snapshot (Associated Press Finance)
08:00AM	Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023 (PR Newswire)
Nov-01-23 08:00AM	Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting 2023 (PR Newswire)
Oct-26-23 08:00AM	Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression (PR Newswire)
Oct-23-23 07:00PM	Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference (PR Newswire)
Sep-19-23 04:05PM	Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference (PR Newswire) -6.12%
Aug-16-23 06:02AM	LPCN: Trial Results Improve Outlook (Zacks)
Aug-10-23 08:09AM	Lipocine: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023 (PR Newswire)
Jul-31-23 06:13AM	LPCN: 1148 Shows Muscle Loss Reversal (Zacks)
Jul-27-23 06:30AM	LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis (PR Newswire) +18.60%
Jun-14-23 08:00AM	Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference (PR Newswire)
Jun-07-23 08:00AM	Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023 (PR Newswire)
May-19-23 09:14AM	LPCN: 1154 Results Illuminate Accelerated Pathway (Zacks Small Cap Research)
May-16-23 07:00AM	Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression (PR Newswire) -17.72%
May-11-23 06:23AM	Lipocine: Q1 Earnings Snapshot (AP Finance) +7.30%
06:00AM	Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023 (PR Newswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Higuchi John W.	Director	Sep 30 '26	Buy	2.23	15,970	35,613	241,365	Oct 01 08:28 PM
Higuchi John W.	Director	Sep 29 '26	Buy	2.15	9,037	19,430	225,395	Oct 01 08:28 PM
Higuchi John W.	Director	Sep 28 '26	Buy	2.16	12,561	27,132	216,358	Sep 30 08:38 PM
Higuchi John W.	Director	Apr 07 '26	Buy	2.03	40,000	81,200	203,797	Apr 07 06:27 PM
Higuchi John W.	Director	Apr 06 '26	Buy	2.05	123,000	252,150	163,797	Apr 06 07:01 PM
Patel Mahesh V.	Chief Executive Officer	Apr 06 '26	Buy	2.03	25,000	50,750	160,679	Apr 06 06:33 PM
Patel Mahesh V.	Chief Executive Officer	Apr 02 '26	Buy	2.02	25,000	50,500	135,679	Apr 02 05:05 PM

Lipocine, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of the delivery of drugs using proprietary delivery technology. It offers TLANDO, an oral testosterone replacement therapy. The company was founded on October 13, 2011 and is headquartered in Salt Lake City, UT.

Co-FounderDr. Mahesh V. Patel Ph.D.

Principal Accounting Officer & Corporate ControllerMs. Krista Fogarty

Senior Vice President of Research & DevelopmentDr. Nachiappan Chidambaram Ph.D.

Vice President of SalesMr. Logan Morse

M.D.Dr. Anthony DelConte M. D.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LPCN

Lipocine Inc

Upgrade your Finviz experience